The effect of ACE inhibitors and ARBs on outcomes in hospitalized patients with COVID-19.
Narges NajafiAlireza DavoudiHamideh IzadyarAbbas AlishahiArmaghan MokhtarianiBahareh SoleimanpourianMina TabarrayiMahmood MoosazadehZahra DaftarianFatemeh AhangarkaniPublished in: Irish journal of medical science (2022)
ACEI/ARB drugs put COVID-19 patients at high risk for moderate to severe forms of COVID-19 and higher length of hospital stay. Although, it is notable that these drugs did not significantly affect specific adverse outcomes of COVID-19, such as the need for admission to the intensive care unit (ICU), length of ICU stay, ventilation, and mortality.
Keyphrases
- sars cov
- coronavirus disease
- mechanical ventilation
- intensive care unit
- respiratory syndrome coronavirus
- emergency department
- healthcare
- cardiovascular events
- drug induced
- early onset
- angiotensin ii
- risk factors
- acute respiratory distress syndrome
- cardiovascular disease
- coronary artery disease
- adverse drug
- metabolic syndrome